Development of quantitative mass spectrometric immunoassay for serum amyloid A

References

• Aldo-Benson MA, Benson MD. (1982). SAA suppression of immune response in vitro: evidence for an effect on T cell-macrophage interaction. J Immunol 128:2390–2.
   PubMed Web of Science ®Google Scholar
• Andersson LO. (1997). Pharmacology of apolipoprotein A-I. Curr Opin Lipidol 8:225–8.
   PubMed Web of Science ®Google Scholar
• Armbruster DA, Pry T. (2008). Limit of blank, limit of detection and limit of quantitation. Clin Biochem Rev 29:S49–52.
   PubMedGoogle Scholar
• Artl A, Marsche G, Lestavel S, et al. (2000). Role of serum amyloid A during metabolism of acute-phase HDL by macrophages. Arterioscler Thromb Vasc Biol 20:763–72.
   PubMed Web of Science ®Google Scholar
• Baba S, Masago SA, Takahashi T, et al. (1995). A novel allelic variant of serum amyloid A, SAA1 gamma: genomic evidence, evolution, frequency, and implication as a risk factor for reactive systemic AA-amyloidosis. Hum Mol Genet 4:1083–7.
   PubMed Web of Science ®Google Scholar
• Badolato R, Wang JM, Murphy WJ, et al. (1994). Serum amyloid A is a chemoattractant: induction of migration, adhesion, and tissue infiltration of monocytes and polymorphonuclear leukocytes. J Exp Med 180:203–9.
   PubMed Web of Science ®Google Scholar
• Bakkaloglu A, Duzova A, Ozen S, et al. (2004). Influence of serum amyloid A (SAA1) and SAA2 gene polymorphisms on renal amyloidosis, and on SAA/C-reactive protein values in patients with familial Mediterranean fever in the Turkish population. J Rheumatol 31:1139–42.
   PubMed Web of Science ®Google Scholar
• Banka CL, Yuan T, DE Beer MC, et al. (1995). Serum amyloid A (SAA): influence on HDL-mediated cellular cholesterol efflux. J Lipid Res 36:1058–65.
   PubMed Web of Science ®Google Scholar
• Betts JC, Edbrooke MR, Thakker RV, Woo P. (1991). The human acute-phase serum amyloid A gene family: structure, evolution and expression in hepatoma cells. Scand J Immunol 34:471–82.
   PubMed Web of Science ®Google Scholar
• Bland JM, Altman DG. (1999). Measuring agreement in method comparison studies. Stat Methods Med Res 8:135–60.
   PubMed Web of Science ®Google Scholar
• Booth DR, Booth SE, Gillmore JD, et al. (1998). SAA1 alleles as risk factors in reactive systemic AA amyloidosis. Amyloid 5:262–5.
   PubMed Web of Science ®Google Scholar
• Carr SA, Abbatiello SE, Ackermann BL, et al. (2014). Targeted peptide measurements in biology and medicine: best practices for mass spectrometry-based assay development using a fit-for-purpose approach. Mol Cell Proteomics 13:907–17.
   PubMed Web of Science ®Google Scholar
• Chau CH, Rixe O, Mcleod H, Figg WD. (2008). Validation of analytic methods for biomarkers used in drug development. Clin Cancer Res 14:5967–76.
   PubMed Web of Science ®Google Scholar
• Cunnane G. (2001). Amyloid precursors and amyloidosis in inflammatory arthritis. Curr Opin Rheumatol 13:67–73.
   PubMed Web of Science ®Google Scholar
• Dossus L, Becker S, Achaintre D, et al. (2009). Validity of multiplex-based assays for cytokine measurements in serum and plasma from unondiseased subjects: comparison with ELISA. J Immunol Methods 350:125–32.
   PubMed Web of Science ®Google Scholar
• Ducret A, Bruun CF, Bures EJ, et al. (1996). Characterization of human serum amyloid A protein isoforms separated by two-dimensional electrophoresis by liquid chromatography/electrospray ionization tandem mass spectrometry. Electrophoresis 17:866–76.
   PubMed Web of Science ®Google Scholar
• Eklund KK, Niemi K, Kovanen PT. (2012). Immune functions of serum amyloid A. Crit Rev Immunol 32:335–48.
   PubMed Web of Science ®Google Scholar
• Farwig ZN, Mcneal CJ, Little D, et al. (2005). Novel truncated isoforms of constitutive serum amyloid A detected by MALDI mass spectrometry. Biochem Biophys Res Commun 332:352–6.
   PubMed Web of Science ®Google Scholar
• FDA. (2001). A guidance for industry – bioanalytical method validation.
   Google Scholar
• Fyfe AI, Rothenberg LS, Debeer FC, et al. (1997). Association between serum amyloid A proteins and coronary artery disease: evidence from two distinct arteriosclerotic processes. Circulation 96:2914–19.
   PubMed Web of Science ®Google Scholar
• Husby G, Marhaug G, Dowtor B, et al. (1994). Serum amyloid A (SAA): biochemistry, genetics and the pathogenesis of AA amyloidosis. Amyloid Int J Exp Clin Invest 1:119–37.
   Web of Science ®Google Scholar
• Johnson BD, Kip KE, Marroquin OC, et al. (2004). Serum amyloid A as a predictor of coronary artery disease and cardiovascular outcome in women: the National Heart, Lung, and Blood Institute-Sponsored Women’s Ischemia Syndrome Evaluation (WISE). Circulation 109:726–32.
   PubMed Web of Science ®Google Scholar
• Kiernan UA, Nedelkov D, Nelson RW. (2006). Multiplexed mass spectrometric immunoassay in biomarker research: a novel approach to the determination of a myocardial infarct. J Proteome Res 5:2928–34.
   PubMed Web of Science ®Google Scholar
• Kiernan UA, Tubbs KA, Nedelkov D, et al. (2003). Detection of novel truncated forms of human serum amyloid A protein in human plasma. FEBS Lett 537:166–70.
   PubMed Web of Science ®Google Scholar
• Kisilevsky R, Subrahmanyan L. (1992). Serum amyloid A changes high density lipoprotein’s cellular affinity. A clue to serum amyloid A’s principal function. Lab Invest 66:778–85.
   PubMed Web of Science ®Google Scholar
• Kluve-Beckerman B, Dwulet FE, Benson MD. (1988). Human serum amyloid A. Three hepatic mRNAs and the corresponding proteins in one person. J Clin Invest 82:1670–5.
   PubMed Web of Science ®Google Scholar
• Liang JS, Sipe JD. (1995). Recombinant human serum amyloid A (apoSAAp) binds cholesterol and modulates cholesterol flux. J Lipid Res 36:37–46.
   PubMed Web of Science ®Google Scholar
• Loo D, Mollee PN, Renaut P, Hill MM. (2011). Proteomics in molecular diagnosis: typing of amyloidosis. J Biomed Biotechnol 2011:754109.
   PubMedGoogle Scholar
• Macgregor AJ, Gallimore JR, Spector TD, Pepys MB. (2004). Genetic effects on baseline values of C-reactive protein and serum amyloid A protein: a comparison of monozygotic and dizygotic twins. Clin Chem 50:130–4.
   PubMed Web of Science ®Google Scholar
• Malle E, Steinmetz A, Raynes JG. (1993). Serum amyloid A (SAA): an acute phase protein and apolipoprotein. Atherosclerosis 102:131–46.
   PubMed Web of Science ®Google Scholar
• Manley PN, Ancsin JB, Kisilevsky R. (2006). Rapid recycling of cholesterol: the joint biologic role of C-reactive protein and serum amyloid A. Med Hypotheses 66:784–92.
   PubMed Web of Science ®Google Scholar
• Marsche G, Frank S, Raynes JG, et al. (2007). The lipidation status of acute-phase protein serum amyloid A determines cholesterol mobilization via scavenger receptor class B, type I. Biochem J 402:117–24.
   PubMed Web of Science ®Google Scholar
• Nelson RW, Borges CR. (2011). Mass spectrometric immunoassay revisited. J Am Soc Mass Spectrom 22:960–8.
   PubMed Web of Science ®Google Scholar
• Nelson RW, Krone JR, Bieber AL, Williams P. (1995). Mass spectrometric immunoassay. Anal Chem 67:1153–8.
   PubMed Web of Science ®Google Scholar
• Niederkofler EE, Phillips DA, Krastins B, et al. (2013). Targeted selected reaction monitoring mass spectrometric immunoassay for insulin-like growth factor 1. PLoS One 8:e81125.
   PubMed Web of Science ®Google Scholar
• Passing H, Bablok. (1983). A new biometrical procedure for testing the equality of measurements from two different analytical methods. Application of linear regression procedures for method comparison studies in clinical chemistry, Part I. J Clin Chem Clin Biochem 21:709–20.
   PubMedGoogle Scholar
• Pizzini C, Mussap M, Plebani M, Fanos V. (2000). C-reactive protein and serum amyloid A protein in neonatal infections. Scand J Infect Dis 32:229–35.
   PubMedGoogle Scholar
• Ristori G, Laurenti F, Stacchini P, et al. (1998). Serum amyloid A protein is elevated in relapsing-remitting multiple sclerosis. J Neuroimmunol 88:9–12.
   PubMed Web of Science ®Google Scholar
• Sellar GC, Jordan SA, Bickmore WA, et al. (1994a). The human serum amyloid A protein (SAA) superfamily gene cluster: mapping to chromosome 11p15.1 by physical and genetic linkage analysis. Genomics 19:221–7.
   PubMed Web of Science ®Google Scholar
• Sellar GC, Oghene K, Boyle S, et al. (1994b). Organization of the region encompassing the human serum amyloid A (SAA) gene family on chromosome 11p15.1. Genomics 23:492–5.
   PubMed Web of Science ®Google Scholar
• Sipe J. (1999). Revised nomenclature for serum amyloid A (SAA). Nomenclature Committee of the International Society of Amyloidosis. Part 2. Amyloid 6:67–70.
   PubMed Web of Science ®Google Scholar
• Skogen B, Natvig JB. (1981). Degradation of amyloid proteins by different serine proteases. Scand J Immunol 14:389–96.
   PubMed Web of Science ®Google Scholar
• Steinmetz A, Hocke G, Saïle R, et al. (1989). Influence of serum amyloid A on cholesterol esterification in human plasma. Biochim Biophys Acta 1006:173–8.
   PubMed Web of Science ®Google Scholar
• Takase H, Tanaka M, Miyagawa S, et al. (2014). Effect of amino acid variations in the central region of human serum amyloid A on the amyloidogenic properties. Biochem Biophys Res Commun 444:92–7.
   PubMed Web of Science ®Google Scholar
• Tolson J, Bogumil R, Brunst E, et al. (2004). Serum protein profiling by SELDI mass spectrometry: detection of multiple variants of serum amyloid alpha in renal cancer patients. Lab Invest 84:845–56.
   PubMed Web of Science ®Google Scholar
• Trenchevska O, Kamcheva E, Nedelkov D. (2010). Mass spectrometric immunoassay for quantitative determination of protein biomarker isoforms. J Proteome Res 9:5969–73.
   PubMed Web of Science ®Google Scholar
• Trenchevska O, Kamcheva E, Nedelkov D. (2011). Mass spectrometric immunoassay for quantitative determination of transthyretin and its variants. Proteomics 11:3633–41.
   PubMed Web of Science ®Google Scholar
• Trenchevska O, Phillips DA, Nelson RW, Nedelkov D. (2014). Delineation of concentration ranges and longitudinal changes of human plasma protein variants. PLoS One 9:e100713.
   PubMed Web of Science ®Google Scholar
• Trenchevska O, Schaab MR, Nelson RW, Nedelkov D. (2015a). Development of multiplex mass spectrometric immunoassay for detection and quantification of apolipoproteins C-I, C-II, C-III and their proteoforms. Methods 81:86–92.
   PubMed Web of Science ®Google Scholar
• Trenchevska O, Sherma ND, Oran PE, et al. (2015b). Quantitative mass spectrometric immunoassay for the chemokine RANTES and its variants. J Proteomics 116:15–23.
   PubMed Web of Science ®Google Scholar
• Uhlar CM, Whitehead AS. (1999). Serum amyloid A, the major vertebrate acute-phase reactant. Eur J Biochem 265:501–23.
   PubMedGoogle Scholar
• Wu TL, I Chen TSAI, Chang PY, et al. (2007). Establishment of an in-house ELISA and the reference range for serum amyloid A (SAA): complementarity between SAA and C-reactive protein as markers of inflammation. Clin Chim Acta 376:72–6.
   PubMed Web of Science ®Google Scholar
• Xie X, Ma YT, Yang YN, et al. (2010). Polymorphisms in the SAA1/2 gene are associated with carotid intima media thickness in healthy Han Chinese subjects: the Cardiovascular Risk Survey. PLoS One 5:e13997.
   PubMed Web of Science ®Google Scholar
• Yamada T, Nomata Y, Sugita O, Okada M. (1993). A rapid method for measuring serum amyloid A protein by latex agglutination nephelometric immunoassay. Ann Clin Biochem 30:72–6.
   PubMed Web of Science ®Google Scholar
• Yamada T, Wada A, Itoh Y, Itoh K. (1999). Serum amyloid A1 alleles and plasma concentrations of serum amyloid A. Amyloid 6:199–204.
   PubMed Web of Science ®Google Scholar
• Yassine HN, Trenchevska O, He H, et al. (2015). Serum amyloid A truncations in type 2 diabetes mellitus. PLoS One 10:e0115320.
   PubMed Web of Science ®Google Scholar
• Zhao Y, He X, Shi X, et al. (2010). Association between serum amyloid A and obesity: a meta-analysis and systematic review. Inflamm Res 59:323–34.
   PubMed Web of Science ®Google Scholar